- In September 2024, Translumina Therapeutics, a leading provider of coronary stents, officially launched operations in the UAE. In partnership with the esteemed German Heart Centre, the company has introduced advanced drug-eluting stent technologies, including the world’s most extensively studied DES, supported by over a decade of comprehensive safety and efficacy research. This strategic collaboration not only strengthens Translumina’s global footprint but also contributes significantly to the ongoing growth and innovation within the global stents market, advancing the availability and effectiveness of cardiovascular treatments worldwide
- In July 2024, MicroPort Scientific Corporation announced that its subsidiary, Shanghai MicroPort Medical (Group) Co., Ltd., had received market approval from the National Medical Products Administration (NMPA) for Firesorb, the first next-generation fully bioresorbable cardiac stent. Pre-market studies demonstrated that Firesorb performed on par with permanent drug-eluting stents in key clinical outcomes, such as success rates and late lumen loss. Firesorb’s introduction is poised to contribute significantly to the global stents market, advancing the development of bioresorbable stents and offering an alternative with improved patient outcomes, while supporting the ongoing growth of minimally invasive cardiovascular treatments worldwide
- In May 2024, Abbott introduced the XIENCE Sierra, a new coronary stent system in India, specifically designed to treat patients with blocked arteries. As an extension of the XIENCE family, this innovative stent system provides enhanced safety for complex cardiac cases. The launch of XIENCE Sierra strengthens Abbott’s position in the global stents market, contributing to the growing demand for high-performance stents that offer improved outcomes, particularly in challenging cardiac conditions
- In May 2022, Abbott announced the launch of XIENCE Skypoint, the only drug-eluting stents (DES) approved in the U.S. designed to enable physicians to deliver advanced technology to patients with larger blood vessels. This innovative stent system enhances treatment options for patients with complex cardiovascular conditions. Abbott’s continued innovation in stent technology contributes significantly to the global stents market, addressing the growing demand for specialized solutions that improve clinical outcomes, particularly in cases involving larger arterial vessels
- In January 2022, Cook Medical announced that it had received FDA Breakthrough Designation for its drug-eluting stent intended for below-the-knee use. This designation recognizes the potential of the stent to address significant unmet clinical needs in treating peripheral artery disease. Cook Medical’s innovation in this area contributes to the global stents market by expanding treatment options for patients with challenging lower extremity conditions, driving the growth of specialized stent technologies, and improving patient outcomes in vascular interventions worldwide
